What Happened
Novo Nordisk's semaglutide tablet became commercially available in U.S. pharmacies on Monday, May 4, under the Ozempic brand. It is the same molecule as the injectable Ozempic and the prior Rybelsus tablet, in three new strengths — 1.5 mg, 4 mg, and 9 mg — with a label that no other oral GLP-1 carries. The pill is approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, whether or not they have had a prior heart attack or stroke. Primary and secondary prevention, in one indication, in a tablet.
The launch consolidates Novo Nordisk's oral and injectable semaglutide products under a single brand for the first time. Rybelsus 7 mg and 14 mg, FDA-approved in October 2025 for cardiovascular risk reduction on the strength of SOUL trial data, has been reformulated and rebranded. A separate 25 mg tablet is under FDA review with a decision expected by the end of 2026. Self-pay pricing through NovoCare runs from $149 per month at 1.5 mg to $299 at 9 mg. Most insured patients pay $25 or less for a 90-day fill.
The Numbers That Matter
- Launch date: May 4, 2026, in U.S. pharmacies.
- New tablet strengths: 1.5 mg, 4 mg, 9 mg under the Ozempic brand. Replaces Rybelsus 3/7/14 mg.
- Pending: 25 mg tablet, FDA decision expected by end of 2026.
- Indication: reduce risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in adults with type 2 diabetes at high cardiovascular risk — primary and secondary prevention.
- Outcomes trial: SOUL, n=9,650, mean follow-up 47.5 months. Primary outcome 12.0% (oral semaglutide) vs 13.8% (placebo); HR 0.86 (95% CI 0.77–0.96, p=0.006); 14% relative risk reduction.
- What drove the result: 26% reduction in nonfatal MI; 12% lower rate of nonfatal stroke; 7% lower CV death.
- Self-pay price (NovoCare): $149 / $199 / $299 monthly for 1.5 / 4 / 9 mg.
- Insured price: as little as $25 for up to a 3-month fill.
What Actually Changed On Monday
The molecule did not change. The label did, the brand name did, and the dose ladder did. Rybelsus tablets — the original FDA-approved oral semaglutide, on pharmacy shelves since 2019 — have been reformulated and rebranded as Ozempic tablets. The new strengths are 1.5 mg, 4 mg, and 9 mg, replacing the older 3 mg, 7 mg, and 14 mg. A bioequivalence study underpinned the dose adjustment.
The reason the rebrand matters is the indication. Rybelsus carried a glycemic-control label and, as of October 2025, a cardiovascular risk reduction label limited to patients with type 2 diabetes at high cardiovascular risk. The Ozempic-branded tablet now carries the cardiovascular indication explicitly across primary and secondary prevention populations. That language — primary and secondary — is the headline. It puts the oral pill on a label parity with the injectable on the cardiovascular question, which is the question that drives most of the prescribing decisions in this class.
For prescribers, this clears up a recurring conversation. A patient with type 2 diabetes and known coronary artery disease who refused injections previously had Rybelsus as the option, but with a narrower CV indication than injectable Ozempic. The oral pill now matches the injectable on label scope. The choice between pill and injection becomes a logistics-and-tolerability decision rather than a label decision.
The Trial That Made This Possible
SOUL is the cardiovascular outcomes trial that did the heavy lifting. It enrolled 9,650 adults aged 50 and older with type 2 diabetes and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, across 450 sites in 44 countries. Participants were randomized to oral semaglutide 14 mg daily or placebo on top of standard care. Mean follow-up was 47.5 months.
The primary outcome was three-point MACE — cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Twelve percent of the semaglutide arm and 13.8% of the placebo arm reached the primary endpoint. The hazard ratio was 0.86, with a 95% confidence interval of 0.77 to 0.96, and the p-value was 0.006. A 14% relative risk reduction. The absolute risk reduction was about 2 percentage points at three years.
The component analysis matters for how the result reads. Nonfatal MI dropped 26%, the largest of the three components and the principal driver of the composite. Nonfatal stroke fell 12% and cardiovascular death fell 7%, neither significant on its own but both directionally consistent. The MI signal lines up with what injectable GLP-1 trials have shown across SUSTAIN-6, REWIND, and PIONEER-6, which suggests the cardioprotective mechanism — whatever it is — rides with the molecule rather than the route of administration.
Subgroup analyses ran clean. The benefit held regardless of baseline SGLT2 inhibitor use, which the trial team analyzed both at baseline and any-in-trial. The hazard ratio was 0.89 in patients on SGLT2i at baseline and 0.84 in those not, with a non-significant p-interaction. That is a useful result for endocrinologists who already prescribe SGLT2 inhibitors and were waiting on data confirming the combination is safe and additive. It is.
Pill Or Shot? The Decision Is Now Almost Purely Practical
Picture a primary-care visit on Tuesday morning. The patient is 64, has type 2 diabetes for ten years, hypertension, a previous TIA, and is on metformin and an SGLT2 inhibitor. The clinician wants to add a GLP-1 agonist with cardiovascular benefit. Until last week, that conversation had a baked-in tension: the strongest cardiovascular labels were on the injectables, the pill was lighter on label scope, and the patient's preference for oral therapy pulled in a different direction from the prescribing trade-off.
That tension just collapsed. The injection still has advantages — once-weekly dosing, predictable absorption, no fasting requirement — and the pill has different ones — no needle, dose flexibility, easier to start and stop. But on the cardiovascular indication, which is the part of the label that moves the prescribing decision in patients like the one above, the two are aligned. Pill or shot is now a tolerability and logistics question.
The catch: oral semaglutide has fasting requirements that the injectable does not. The original Rybelsus label requires it to be taken on an empty stomach, with no more than a small amount of water, and at least 30 minutes before any other food, drink, or medication. The Ozempic-branded tablet inherits the same absorption profile. Pediatric use is not approved. Gastrointestinal side effects — nausea, diarrhea, constipation — are the same for the pill as for the shot. None of this disqualifies the option, but the empty-stomach window is a real adherence variable for some patients and worth surfacing in the prescribing conversation.
The Price Picture
For most insured patients with type 2 diabetes, Novo Nordisk says the cost is $25 or less for up to a 3-month prescription. That is the headline number for commercial insurance and Medicare Part D plans that cover the drug. Coverage and copay vary widely by formulary placement, prior authorization rules, and step therapy.
For self-pay patients buying through NovoCare Pharmacy or select telehealth providers, monthly tablet pricing is $149 at 1.5 mg, $199 at 4 mg, and $299 at 9 mg. Government beneficiaries are excluded. The self-pay scaffolding sits next to the company's existing $499-per-month self-pay program for the injectable.
Two pricing observations are worth flagging. First, the self-pay tier closes a gap that compounded semaglutide and unapproved research-peptide vendors were filling. A patient willing to pay $300 a month at 9 mg has an FDA-approved option that did not effectively exist before. Second, payer math shifts. CMS spent over $14 billion on GLP-1s for diabetes in 2024, almost all of it on injectables. A pill option with the same cardiovascular label changes step-therapy arithmetic in ways that formulary committees will work through over the next year.
Where This Lands In The Wider GLP-1 Story
The class is consolidating into a recognizable hierarchy. Tirzepatide sits at the top of the cardiometabolic gradient as a dual GIP/GLP-1 agonist, with SURPASS-CVOT data in hand. Semaglutide — in either route of administration — sits next, with cardiovascular outcomes data across SUSTAIN-6 (injectable), PIONEER-6 (oral, neutral), SELECT (injectable, in obesity without diabetes), FLOW (injectable, kidney outcomes), and now SOUL (oral, MACE in T2D with high CV risk). Dulaglutide trails on hard MACE based on REWIND and the recent 75,243-patient Medicare comparison we covered yesterday. Liraglutide, the older once-daily injectable, has LEADER and a smaller market share each year as the once-weekly agents move ahead.
Two newer agents are reshaping the back half of the year. Lilly's orforglipron, the first non-peptide oral GLP-1 partial agonist, was approved on April 1, 2026, under the FDA's National Priority Voucher pilot for chronic weight management. It is not a peptide and falls outside this site's scope, but it changes the oral-GLP-1 competitive map directly. Lilly's retatrutide — the triple agonist of GIP, GLP-1, and glucagon — has Phase 3 weight-loss data and a pending cardiovascular outcomes trial.
For the regulated branded GLP-1 class, the evidentiary picture keeps tightening. For the unregulated end of the peptide universe — the BPC-157, MOTS-c, and similar compounds the FDA's PCAC docket will discuss in July — the picture remains thin. The two ends of the peptide regulatory map keep moving in opposite directions, and this week's commercial launch is one more datapoint on the regulated end.
Frequently Asked Questions
Is the Ozempic pill the same drug as the Ozempic injection?
Same molecule, different route. Both deliver semaglutide. The injection is once weekly subcutaneous; the pill is once daily oral and absorbed through the stomach with the help of an absorption-enhancing co-formulant. Pharmacokinetics differ — the oral form needs an empty stomach and a 30-minute window before food — but the cardiovascular indication, after this week, looks similar across both forms.
What happened to Rybelsus?
Rybelsus is being reformulated and rebranded as Ozempic tablets in 1.5, 4, and 9 mg strengths. The new pills replace the Rybelsus 3, 7, and 14 mg strengths over time. The molecule and absorption mechanism are the same. The 25 mg tablet under FDA review is a separate higher-dose program with a decision expected by year-end.
Does the SOUL trial change clinical practice?
Yes, in two specific ways. It establishes that the cardiovascular benefit of the GLP-1 class extends to oral semaglutide, which had been an open question after the smaller, neutral PIONEER-6 trial. And it broadens the eligible population from secondary prevention to high-risk primary prevention. For patients with type 2 diabetes at elevated cardiovascular risk who have not yet had a heart attack or stroke, oral semaglutide now has supportive outcomes data the older oral GLP-1 indication did not.
How does this compare to the new Medicare semaglutide vs dulaglutide study?
The Medicare comparison was a propensity-matched observational study of 75,243 older adults that found injectable semaglutide cut three-point MACE 22% versus dulaglutide. The SOUL trial is randomized placebo-controlled evidence for the oral form. The two findings tell consistent stories: semaglutide has a strong cardiovascular signal across routes of administration and across study designs, and that signal is larger than what older agents in the class have produced.
Will insurance cover the Ozempic pill?
Most commercial and Medicare Part D plans that already cover Rybelsus will transition coverage to the Ozempic-branded tablet, often at the same tier and copay. Patients should check their plan formulary. Step-therapy and prior-authorization rules vary; if a payer pushes back on cardiovascular indication coverage, the SOUL trial publication and the updated FDA label are the documents prescribers will reference.
What about peptide compounding pharmacies?
The Ozempic pill is FDA-approved and is not subject to the compounding-pathway rules that apply to research peptides. The FDA's separate, ongoing 503B and 503A peptide-compounding work is a different regulatory question that affects unapproved peptides and outsourcing facilities. See our FDA 503B GLP-1 proposal coverage for that story.
Sources
- Novo Nordisk press release, May 1, 2026: Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the U.S. PR Newswire
- BioSpace, October 17, 2025: FDA approves Novo Nordisk's oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event. BioSpace
- McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SOUL). NEJM, March 2025. PubMed 40156843
- American College of Cardiology, March 29, 2025: SOUL trial summary — oral semaglutide reduces cardiovascular events 14% at four years. ACC.org
- FDA press release, April 1, 2026: First new molecular entity approved under National Priority Voucher (orforglipron / Foundayo). FDA.gov
Sources & References
- FDA PCAC Meeting Announcement (July 23-24, 2026)
- PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr.
- BioPharma Dive: FDA Peptides RFK Advisory Committee Restrictions
- RAPS: FDA Considers Adding a Dozen Peptides to Bulk Drug List
- Ars Technica: RFK Jr. Forces FDA to Reconsider 12 Peptides
- ProPublica: Peptide Safety Investigation
- New York Times: Peptide Ban FDA RFK Jr.
- SSRP Institute: FDA Announces Change in Status of 12 Peptides
- CNBC: RFK Jr. Peptides Hims Hers GLP-1
- USA Today: RFK Jr. FDA Peptides Explainer
